Navigation Links
Roche Scientist Recognized for Excellence in Peptide Chemistry
Date:10/7/2009

BOULDER, Colo., Oct. 7 /PRNewswire/ -- Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored last week as the 2009 recipient of the Meienhofer Award for excellence in peptide chemistry at the international peptide symposium, RCCPS (http://www.rochecolorado.com/PeptideSymp09/). Hosted by Roche Colorado, the company's peptide manufacturing facility in Boulder, RCCPS is the only global conference exclusively dedicated to peptides. For Danho, who has a world-wide reputation as a leader and innovator in the field of peptide chemistry and the application of peptide chemistry to drug discovery, this was the second prestigious award he garnered this year.

"Each year, the world's leading peptide scientists honor one of their own at RCCPS for a lifetime of outstanding achievement," said the symposium's co-chair, Ralph Di Libero. "The selection of Waleed as the 2009 Meienhofer Award recipient is particularly compelling as it speaks volumes to the central role that Roche is playing, through all stages of drug development, at demonstrating the viability of synthetic peptide therapeutics."

This theme was echoed by Danho. "There were many who doubted the viability of synthetic peptides, relegating promising medicinal compounds to the shelf. Roche kept its faith in my vision for the future of peptides and their faith is beginning to bear fruit, with many synthetic peptides now providing meaningful health benefits and many more in the pipeline."

"Of course," concluded Danho, "I accept this tribute with due respect for my colleagues in the peptide field who helped advance the science to its present place of influence in the pharmaceutical industry. That is what makes the Meienhofer Award, receiving it as I did during this premier gathering of peptide scientists, such a meaningful tribute."


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
3. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
4. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
7. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
8. MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
11. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician associations ... doctors the survival tools they need to provide demonstrably ... today,s health care marketplace. "I am confident ... local practices," said Stephen L. Brotherton ... " Texas doctors are determined to ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
(Date:5/23/2013)... May 23, 2013  Ameritox, the nation,s leader ... Progressive Medical, Inc. to become part of its ... manage pharmacy costs and improve the clinical outcomes ... leading pharmacy benefit manager in the workers, compensation ... compliance and pain management strategy for several years. ...
Breaking Medicine Technology:TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... Cobos, MD, a board certified dermatologist and associate professor ... today that her patients are experiencing tremendous results with ... skin tightening and contouring, features a new vibrating hand ... , "Thermage has always been popular with my ...
... Cardiac Science Corporation (Nasdaq: CSCX ... AED ) and diagnostic cardiac monitoring devices, announced today ... its board of directors. Andrews replaces long-time board member Jue-Hsien ... November 5th. The total number of directors remains at six. ...
Cached Medicine Technology:Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 3Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 4Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 5
(Date:5/23/2013)... Jersey (PRWEB) May 23, 2013 If ... suffering from irritable bowel syndrome (IBS), the food spread ... your holiday fun. , “While hot dogs and ice ... during the warm weather months, IBS sufferers often feel ... Deborah Sokol, MD, a gastroenterologist with Lourdes Medical Associates. ...
(Date:5/23/2013)... Salt Lake City, UT (PRWEB) May 23, 2013 ... RADPrimer 3.0 , a comprehensive radiology learning environment ... RADPrimer, with prebuilt lessons and assessments, transforms the ... more comprehensive radiology curriculum. , “Until ... that is second to none,” comments Dr. B.J. ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
(Date:5/23/2013)... while being dragged to its destruction inside a ... sending signals that thwart the development of tumor-suppressing ... an early online publication at Nature . ... by tumors, the epidermal growth factor receptor (EGFR) ... team led by scientists at The University of ...
(Date:5/23/2013)... York, New York (PRWEB) May 23, 2013 ... manufactured by C.R. Bard, Inc., continue to move forward ... Court, Southern District of West Virginia, Bernstein Liebhard LLP ... the Court denied a request by C.R. Bard to ... would reveal trade secrets and other confidential, proprietary information ...
Breaking Medicine News(10 mins):Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... is an economically priced 2-channel data ... research use in the fields of ... biology, zoology, biochemistry and biomedical engineering. ... signal conditioners and transducers. Two Pod ...
... The PowerLab/16SP is a high-performance recording unit ... science research applications that require up to ... and isolated tissue studies. The unit is ... to 200 000 samples per second continuously ...
... data acquisition system suitable for a wide ... animal physiology, pharmacology, neurophysiology, biology, zoology, biochemistry, ... of recording from very slow to very ... per second continuously to disk), and is ...
Medicine Products: